Investor sentiment has turned toward a steady bullish outlook. Main Street sentiment is also turning rapidly to embrace the idea that we are not on the verge of an imminent recession. Inflation has come all the way back down to near the Fed’s target zone, and the Fed appears to be preparing for its last rate hike of the cycle later this month, according to Fed Funds Futures date from the CME.
By all accounts, a new bull market is now well underway. But investor exposure remains shallow in the market. Now is the time to be on the hunt for new growth opportunities, especially among small caps that have yet to be discovered by the crowd.
One interesting small cap on the Nasdaq, still trading under $2/share but with growing sales and a growing brand footprint in an explosive growth market, is Mangoceuticals, Inc. (NASDAQ: MGRX).
MGRX is a rising star in the men’s health and wellness space, which is worth over $30 billion worldwide and is growing at a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. The stock is especially interesting because it has a unique angle on the ED market and has been on a rampage in terms of rising brand awareness but hasn’t yet posted a breakout quarter that catches everyone’s attention.
In other words, it’s still flying under the radar. But this earnings season could be the moment when everyone starts to take notice.
Under the Radar, but Not for Long
While shares of MGRX are still under the radar, the company’s brand has been breaking out with a series of growth-oriented campaigns that act as part of its intense new focus to drive exponential sales growth in the quarters ahead.
Much of this has to do with high-profile marketing and public awareness exposure that the company has put together, and continues to expand, over the past couple of months. In that time, the CEO has rung the bell on the stock exchange on CNBC, been slated for appearances on Fox Business and Bloomberg TV, partnered with Gronk’s Ice Shaker brand, and become a featured sponsor on Barstool Sports and the “Only Stans” podcast sensation.
The company has also launched its “Make America Hard Again” campaign, which will be augmented by a dedicated web presence and a promise to the campaign into its other marketing efforts to drive a nationwide movement for men’s health and wellness that feeds back into awareness around the company’s products.
All of this follows the company’s recently concluded successful IPO on the Nasdaq, which generated $5,000,000 in gross proceeds earmarked to fund product awareness and operational expansion as the company launches its flagship product: Mango, a groundbreaking solution designed to address men’s unique concerns.
In fact, not only is the launch of Mango already driving growth, but the company has already expanded its core ED offering to position itself for further market share penetration.
A Better Way
Unlike competitors offering generic ED medications, Mangoceuticals takes pride in creating its own expertly formulated compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations.
In other words, this is a disruptive model. Original Mango offers a special formulation featuring the same active ingredient as in Cialis™ (Tadalafil) along with other FDA approved ingredients to maximize results. And it’s all packaged in a rapidly dissolving tablet that is absorbed orally and is capable of producing results in 15 minutes, with effects lasting up to 36 hours.
However, just a few weeks ago, the company announced the upcoming release of its second Mango ED product leveraging its existing custom compound alongside Sildenafil, which is the active ingredient found in Viagra™. This one will also be delivered, like original Mango, in a rapidly dissolving mango-flavored tablet that activates and dissolves orally for immediate action.
The other interesting edge the company has is its unique telemedicine platform.
Mango is a prescription medication that must be approved by a physician. But the company has set up a telehealth infrastructure to aid in that process: After an individual has completed an online telehealth visit, MGRX’s network of medical providers will review and approve a prescription if medically appropriate, and then send the product immediately to the customer.
Conclusion
MGRX may well have the best-of-breed product in its space right now, delivering faster results, without the uncomfortable aspects of the process normally faced by ED patients.
At present, this is a cheap Nasdaq small cap with a disruptive angle targeting a $31 billion space growing at 15% CAGR. MGRX is packaging its unique strategy in a powerful vision with strong taboo-free messaging, and it’s starting to get a lot of attention.
The company’s commercial-stage operations are just starting to blossom. Once it adds clear signs of strong topline growth to this equation, investors may find they have to chase a new momentum favorite.
But all the pieces may already be in place now, while the stock is still flying under the radar. MGRX is worth a close look as the new bull market gets its legs.
